Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Automated detection of referential features in schizophrenic speech using large language models.

Neuropsychologia·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

HemaSphere·2026
Same author

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.

Leukemia & lymphoma·2026
Same author

Inhibition of SUV39H1 as a potent therapeutic target in multiple myeloma.

Haematologica·2026

Related Experiment Video

Updated: May 14, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.2K

CAR-T Cells: Current Status, Challenges, and Future Prospects.

Aya Sedky Adly1, Guillaume Cartron2, Afnan Sedky Adly3

  • 1IRMB Univ Montpellier, INSERM Montpellier France.

Medcomm
|April 20, 2026
PubMed
Summary

Artificial intelligence (AI) is revolutionizing chimeric antigen receptor (CAR)-T cell therapy by addressing challenges like toxicity and resistance. This integration promises safer, more effective cancer treatments through computational optimization.

Keywords:
algorithmand machine learningchallengeschimeric antigen receptormechanismstrogocytosis

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

1.0K

Related Experiment Videos

Last Updated: May 14, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

4.0K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

1.0K

Area of Science:

  • Immunotherapy
  • Computational Biology
  • Oncology

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy is a rapidly expanding cancer treatment.
  • Current CAR-T therapy faces challenges including toxicity, resistance, and accessibility.
  • Human intervention alone is insufficient to fully optimize CAR-T cell therapy outcomes.

Purpose of the Study:

  • To provide a comprehensive review merging CAR-T cell biology with artificial intelligence (AI).
  • To investigate challenges in current CAR-T therapies and how AI can address them.
  • To guide the development of safer and more effective CAR-T therapies through integrated approaches.

Main Methods:

  • Review of mechanistic foundations of CAR-T cells.
  • Investigation of challenges in CAR-T therapies (toxicity, resistance, accessibility).
  • Examination of AI applications in CAR-T engineering and clinical management, including case studies.

Main Results:

  • AI offers novel computational interventions to refine CAR-T therapeutic mechanisms.
  • AI-based innovations are being utilized to optimize CAR-T engineering and clinical management.
  • Studies incorporating AI show promise in enhancing therapeutic mechanisms and outcomes.

Conclusions:

  • Integrating AI with CAR-T cell mechanistic biology offers a unified perspective for improvement.
  • AI can help overcome limitations in current CAR-T therapies, leading to better efficacy.
  • This integrated approach is crucial for developing next-generation, safer, and more effective CAR-T treatments.